PR Newswire
LONDON, United Kingdom, May 01
1 May 2026
THE BIOTECH GROWTH TRUST PLC
(«BIOG» or the «Company»)
ARCHIMED to acquire BIOG portfolio company, Esperion Therapeutics.
The Company notes the announcement on Friday, 1 May 2026 that ARCHIMED has
entered into an agreement to acquire BIOG portfolio company, Esperion
Therapeutics («Esperion») for approximately $1 billion, or $3.16 per share, in
cash, representing a 58% premium to Esperion’s closing price on Thursday, 30
April 2026. The offer also includes an additional $100 million in contingent
value right payments which are based on Esperion products achieving certain
sales milestones; if met, the aggregate purchase price would total $1.1 billion.
Esperion is a US-based commercial biopharmaceutical company focused on drugs
targeting cardiovascular disease. Its lead drugs are oral therapies to lower
cholesterol.
The Company’s holding in Esperion represented 2.5% of the Company’s net asset
value («NAV») at the time of the announcement. The transaction will be reflected
in the Company’s NAV as at close of business on 1 May 2026, which will be
announced onTuesday, 5 May 2026.
This follows on from recent acquisitions of portfolio companies Avidity
Biosciences, Cidara Therapeutics, Amicus Therapeutics, Apellis Pharmaceuticals
and KalVista Pharmaceuticals.
To sign up for BIOG updates by email, please click
here (https://www.biotechgt.com/media/email-alerts).
Enquiries:
SEC Newgate (George Esmond)
Public Relations
020 3757 6894
Frostrow Capital LLP
Company Secretary
020 3709 8734
This information was brought to you by Cision http://news.cision.com
